FDA Clears Rare Disease Breakthroughs in Rapid-Fire Week

The FDA is having a banner week for rare disease treatments, greenlighting multiple therapies that could transform outcomes for small patient populations previously left with few options.

Prescribed Reading

IntraBio's Aqneursa gains FDA approval for ataxia-telangiectasia, a rare and progressive genetic disorder that attacks the nervous and immune systems. The privately held biotech's treatment represents a new therapeutic...